Pure Biologics S.A. (WSE:PUR)
Poland · Delayed Price · Currency is PLN 4.240
+0.020 (0.47%)
At close: Dec 5, 2025
Pure Biologics Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
7
Market Cap
34.61M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 662.00K | 408.00K | 160.63% |
| Dec 31, 2021 | 254.00K | -318.00K | -55.59% |
| Dec 31, 2020 | 572.00K | -1.20M | -67.79% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| NEUCA | 13.34B |
| Diagnostyka | 2.30B |
| Centrum Medyczne ENEL-MED | 820.59M |
| Synektik Spólka Akcyjna | 623.20M |
| Voxel | 568.83M |
| Selvita | 373.90M |
| Celon Pharma | 225.60M |
| Ryvu Therapeutics | 90.41M |